A Regulatory Reversal Lifts uniQure
The day's biggest jolt came from gene therapy maker uniQure, whose shares surged 66% after the FDA delivered what Endpoints News called "surprise good news": the company is now one step closer to marketing its Huntington's disease treatment. The turnaround follows the overturning of an earlier rejection — described by Ars Technica's reporting as "truly evil" — in the wake of leadership changes at the agency. With a key official's exit, the path to approval reopened, and investors responded immediately. It's a sharp reminder of how much regulatory posture, not just clinical data, shapes a biotech's fortunes.
Big Money, Bigger Bets
Dealmaking ran hot. Jazz Pharmaceuticals tied up with Canadian antibody developer AbCellera in a partnership worth up to $4.1 billion, centered on T cell engagers — a class of antibody-based therapies. On the clinical front, F2G and Shionogi reported that their antifungal olorofim succeeded in a pivotal Phase 3 trial, a meaningful win in a field where new options are scarce.
Fresh capital flowed too. Vedana Therapeutics emerged from stealth with $46 million in Series A funding, chasing what it frames as a tougher goal than current migraine drugs: stopping the headaches entirely. And Innoviva, a healthcare asset and royalties holding company, is reviving Lyndra's long-acting oral drug delivery platform — a technology that once drew hundreds of millions before stalling, now getting a second life.
AI Moves Deeper Into Drug Discovery
Artificial intelligence threaded through the day's headlines. South Korea's LG was especially busy: LG AI Research agreed to work with D&D Pharmatech on next-generation peptide drugs, while LG Chem signed a deal with UK biotech LabGenius to hunt for cancer treatments using its AI-powered platform. Eli Lilly's TuneLab, which the company bills as a first-of-its-kind AI initiative, crossed 100 members and added Chai's models to its lineup — a sign that collaborative AI drug-discovery networks are gaining real scale.
The most unexpected entrant was Midjourney. Best known for turning text prompts into artistic images, the company unveiled Midjourney Medical, a project generating full-body ultrasound scans rather than the cat pictures and illustrations that made its name. Whether a generative-image firm can credibly pivot into clinical imaging is an open question, but the ambition underscores how broadly AI players now see healthcare as their next frontier.
A Hack, and a Warning Shot
Not all the AI news was upbeat. Novo Nordisk, the Danish drugmaker behind some of the world's best-known medicines, has been hit by a cyberattack and is now being extorted by those claiming responsibility. The attackers say they made off with the company's AI models and manufacturing recipes — a pointed illustration of how the same proprietary AI assets now driving pharma's competitive edge have become prime targets for theft.
The Bigger Picture
Stepping back, The Washington Post's AI & Tech Brief, published by WP Intelligence, trained its lens on China's growing dominance in biotechnology in the AI era. Taken together with the day's flurry of cross-border AI partnerships — Korean conglomerates, Canadian and British biotechs, American pharma giants — the story of June 18 is one of an industry racing to fuse artificial intelligence with drug development, even as it learns the costs of doing so. From a regulatory rescue to a multibillion-dollar antibody bet to a data heist, the throughline is unmistakable: AI is no longer a side experiment in pharma. It's the main event, and everyone is scrambling for position.